SL-327

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameSL-327
Drug Alias NameSL-327
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 1Dual specificity mitogen-activated protein kinase kinase 2
Therapy Area/IndicationsCerebral Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Pharma Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Pharma CompanyBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsCerebral Infarction

Other Information

ATC CodeN/A
Related LinksN/A